Ask Jason
Introduction: Why This Matters to You Right Now
If you manage workers compensation claims in NSW, you've heard about SIRA's medication management guidelines. But knowing the guideline exists and knowing what to actually do on Monday morning with an opioid-heavy claim are two very different things.
Here's the reality: approximately 1 in 5 injured workers with back or neck injuries in NSW are prescribed opioids within the first three months of their claim. Of those, two out of three receive early high-risk opioid prescriptions, high doses, long-acting formulations, or concurrent psychotropic medications. And nearly a quarter of injured workers prescribed opioids are still on them a year later.
That's not just a clinical concern. It's a claims management issue. It affects your liability, your costs, your outcomes, and your ability to defend your decision-making if a dispute arises.
This guide walks you through what SIRA actually requires, what it means for your claims handling workflow, and how to build medication monitoring into your process from day one.
What SIRA Actually Says About Opioids
SIRA's Medication Management in the NSW Personal Injury Schemes: Better Practice Guide doesn't single out opioids as uniquely problematic. But it does place them squarely in the high-risk category, alongside benzodiazepines, medicinal cannabis, injectable narcotics, and medication-assisted treatment of opioid dependency.
Here's what the guideline requires:
1. PBS Must Be the Default Position
Unless there's a documented clinical reason otherwise, injured workers should receive medications under the Pharmaceutical Benefits Scheme (PBS), not private prescriptions.
For opioids, this matters because:
- Most common opioids used in workers comp (paracetamol/codeine combinations, tramadol, oxycodone) have PBS listings with defined dosing limits and supply restrictions
- PBS-listed medications create a transparent, auditable supply record
- Private opioid prescribing without documented clinical justification signals prescriber risk
Your action: If an injured worker is prescribed an opioid privately, you should ask the treating doctor: "Why isn't this available via PBS?" If their answer is vague or missing, that's a red flag.
2. Private Prescriptions Must Have Written Clinical Rationale
If a private opioid prescription is justified, SIRA requires the prescriber to document in writing to you (the insurer) why it was necessary. "Because I prefer it" is not an acceptable answer. "Because the patient needs a dose above PBS maximum" or "Because of documented drug interaction with their other medication" is.
Your action: Request the written rationale in writing. If the prescriber resists, treat that as a compliance issue and consider whether you continue funding that prescriber's opioid scripts.
3. Pharmacy Review Is Recommended for Opioid Claims
This is where claims managers often go wrong. They think "pharmacy review" means waiting until there's a problem. Actually, SIRA recommends proactive review when:
- High-risk medications (including opioids) are being supplied
- Multiple prescribers or pharmacies are involved in the claim
- The injured worker has comorbidities (psychiatric, cardiovascular, respiratory conditions)
- Opioid doses exceed manufacturer-recommended maximums
- Opioids are being prescribed concurrently with other psychotropic medications (benzodiazepines, antidepressants, antipsychotics)
Your action: These aren't conditions to wait and see about. They're triggers to initiate a pharmacy review early, within weeks of the prescription, not months.
4. Suspected Overprescribing Gets Reported
If a pharmacist review (or your own observation) suggests a prescriber is regularly overprescribing opioids, SIRA expects you to refer that prescriber to the Health Care Complaints Commission or their relevant professional council.
Your action: Document patterns. If a particular GP writes high-dose, long-acting opioid scripts for multiple injured workers on your book, that's a referral-worthy pattern. It's part of your duty as a responsible claims manager.
When to Trigger a Pharmacy Review: Your Decision Framework
The most common mistake claims managers make is treating pharmacy review as something you do when a problem is obvious. But by then, the problem is entrenched. SIRA's approach is preventive.
Use this framework to decide: Do I initiate a pharmacy review now or wait?
| Claim Scenario | SIRA Position | What You Should Do |
|---|---|---|
| Worker prescribed opioid (any strength) for back/neck injury, first 3 months | High-risk medication identified | Initiate review. This is your baseline trigger. Don't wait. |
| Opioid dose approaching or exceeding manufacturer max (e.g., >240 mg/day tramadol) | Problematic prescribing | Initiate review immediately. This is a clear safety signal. |
| Multiple prescribers OR multiple pharmacies supplying opioids | High-risk pattern | Initiate review. Fragmented care increases overdose risk. |
| Opioid + benzodiazepine prescribed concurrently | Serious safety concern | Urgent review. This combination carries respiratory depression risk. Escalate. |
| Worker has psychiatric history, sleep apnoea, or respiratory disease + opioid | Comorbidity risk | Initiate review. These populations have higher overdose risk. |
| Opioid prescribed at month 6 with no apparent progress to recovery | Prolonged high-risk exposure | Initiate review and consider strategy shift. Ongoing opioids can delay recovery. |
How Your Claims Handling Actually Changes: The Practical Workflow
Understanding SIRA's position and actually changing how you work are different things. Here's what changes:
1. On Day 1 of the Claim: Set the Medication Framework
What you do:
When you receive notification of the claim, ask the treating doctor: "Is this worker on any medications? If so, what, and why?" Get this in writing in your first communication.
Why it matters:
You're establishing the baseline. If opioids appear in the first 2 weeks, you're not reacting to a surprise. You're aware and documented.
Red flags to note:
- Opioid prescribed immediately without other pain management attempted first
- High dose from the outset
- Long-acting formulation (when short-acting would be appropriate)
- Private prescription without explanation
2. At Month 1: Assess and Document
What you do:
If opioids are in the picture, document: which opioid, what dose, what other medications, how many prescribers/pharmacies, any comorbidities you're aware of.
Why it matters:
You're building the clinical picture. This is when you decide: early review needed, or monitoring sufficient?
Decision point:
Does this claim hit one of your review triggers (see framework above)? If yes, commission a pharmacy review now, not at month 3.
3. If a Pharmacy Review Is Commissioned: Demand Action, Not Just a Report
What you do:
When you engage a pharmacist to review, don't just ask for a report. Ask for a medication management strategy, a plan that includes recommendations to the treating doctor, a timeline, and proposed follow-up.
Why it matters:
A report is passive. A strategy is active. The best pharmacy reviews include direct communication with the prescriber, not just a letter to you.
Implementation:
Look for a provider that will:
- Review the whole picture (medications, comorbidities, recovery progress)
- Communicate findings directly with the treating doctor (by phone, not just letter)
- Provide written recommendations to you
- Follow up to confirm the prescriber's response
4. At Months 2-3: Monitor and Adjust
What you do:
Check: Has the prescriber implemented any of the pharmacist's recommendations? Is the opioid dose stable, increasing, or decreasing? Is there progress toward functional recovery, or is the worker remaining opioid-dependent?
Why it matters:
SIRA compliance requires active monitoring, not just point-in-time review. You're demonstrating duty of care.
Action point:
If the prescriber ignored the pharmacist's recommendations, that's a compliance issue. Document it and consider escalation.
5. By Month 6: Evaluate Strategy
What you do:
If the worker is still on opioids at month 6, step back. Ask: Is this opioid still appropriate? Is it helping recovery, or prolonging dependence? Has the injury recovered enough to taper? Are there alternatives (physio, pain psychology, non-opioid medications)?
Why it matters:
Opioid continuation needs active justification after acute phase. SIRA expects claims managers to challenge ongoing opioid use, not just accept it.
Next step:
Second medication review, or direct discussion with prescriber about recovery trajectory and opioid role.
Real-Time Prescription Monitoring: Your SIRA Compliance Tool
Here's something most claims managers don't realise: You don't have to wait for pharmacy invoices to see medication trends.
Victoria has SafeScript. Queensland has QScript. These are real-time prescription monitoring systems that pharmacists can access immediately to see:
- All Schedule 8 medications (including strong opioids) a patient has been dispensed in the past 12 months
- All prescribers who have written for the patient
- All pharmacies that have dispensed to the patient
- Any "doctor shopping" (multiple prescribers for the same medication)
- High-risk prescribing patterns (high doses, long-acting formulations, concurrent depressants)
If you're working in Victoria or Queensland with an opioid claim, a pharmacist with SafeScript or QScript access is a game-changer. They can identify risk in real time, not weeks later from invoices.
Your action: When you commission a medication review for an opioid claim, ensure the pharmacist has (or will access) the relevant state-based real-time monitoring system. It's not just about the review, it's about ongoing monitoring and early warning.
Data That Should Change Your Perspective on Opioid Claims
If you're still uncertain whether SIRA's emphasis on opioid management is justified, here's the data:
- 20.5% of injured workers with back/neck injuries receive opioid prescriptions within the first 3 months
- 67.1% of those opioid-prescribed workers receive early high-risk prescribing (high dose, long-acting, or concurrent psychotropics)
- 22.8% of workers prescribed opioids are still using them 12+ months later
- Injured workers in regional/remote areas are significantly more likely to receive high-risk opioid prescribing than those in major cities
- Socioeconomic disadvantage is associated with prolonged opioid use in injured workers
Translation: Opioid prescribing to injured workers isn't just common, it's commonly problematic. If you're managing claims without a systematic approach to opioid identification and review, you're exposed to liability, cost overruns, and poor outcomes.
Your SIRA Opioid Implementation Checklist
Use this checklist as your internal standard. Train your team to these points. Audit your claims against this framework.
Claim Initiation
- ☐ First communication to treating doctor includes question: "Is this worker on any medications?"
- ☐ Any opioid prescription is documented in the claim file with date, prescriber, drug, dose, frequency
- ☐ Private opioid prescriptions are flagged for clinical justification check
Months 1-3: Early Identification & Review Trigger
- ☐ Any opioid prescription is reviewed against SIRA triggers (above)
- ☐ Pharmacy review is initiated if any trigger is met (opioid + high risk)
- ☐ Review is commissioned with a pharmacist who will engage directly with the prescriber
- ☐ If SafeScript/QScript available (VIC/QLD), pharmacist accesses real-time data
Months 3-6: Monitoring & Strategy Implementation
- ☐ Pharmacist recommendations are documented in the claim file
- ☐ Treating doctor's response to recommendations is tracked (implemented, ignored, modified?)
- ☐ Opioid dose trend is monitored (stable, increasing, decreasing, tapering?)
- ☐ Functional recovery progress is assessed in context of medication use
- ☐ If prescriber ignored recommendations, issue is escalated or follow-up communication made
Month 6+: Strategy Evaluation
- ☐ Ongoing opioid use is actively justified in the claim file
- ☐ If worker is still opioid-dependent at month 6, strategy review is conducted
- ☐ Second medication review (or direct prescriber discussion) is commissioned if needed
- ☐ Transition planning (dose reduction, alternative medications, psychology support) is documented
Compliance & Escalation
- ☐ Any overprescribing pattern is documented
- ☐ If prescriber pattern warrants it, Health Care Complaints Commission referral is made
- ☐ All decisions (to review, not review, to escalate) are documented in writing
What Gets Better When You Do This
Claims managers sometimes worry that implementing SIRA's opioid framework will be costly and burdensome. In practice, the opposite happens:
Better Clinical Outcomes
Workers recover faster when opioid use is optimised early. You're not just reducing risk, you're supporting better recovery trajectories.
Lower Long-Term Costs
Early intervention prevents prolonged opioid dependence, which is expensive to manage and slow to resolve. The cost of a pharmacy review at month 2 is far less than the cost of managing an opioid-dependent worker 12 months in.
Defensible Decision-Making
When a dispute arises (and they do), you can demonstrate that you identified the opioid risk, commissioned expert review, engaged the prescriber, and monitored the outcome. That's a legally strong position.
Reduced Regulatory Risk
You're not just complying with SIRA guidelines, you're demonstrating that you're actively managing one of the highest-risk medication categories in workers comp. That protects your reputation and your underwriting.
Stronger Relationships with Treating Doctors
Doctors respect claims managers who are informed and engaged, not obstructive. Early, professional pharmacist communication about opioid prescribing is usually welcomed, not resisted. It signals that you care about the worker's outcome, not just cost control.
